Boehringer Ingelheim and CureVac announce collaboration.

NCI is “really, really sturdy” and won’t break, former directors Ned Sharpless and Kim Rathmell say at UNC Lineberger symposium

Grants are flowing out of NCI again to beat the fiscal-year end deadline and some cancer researchers are starting to feel cautiously optimistic about the future.

September 19, 2025

Vol.51 No.34

By Paul Goldberg

NCI

NCI releases names of members of ad hoc working group—filling the void left by BSA

NCI has released the names of the members of the newly formed ad hoc Working Group on Extramural Research Concepts and Programs. The group will perform the peer review functions of the now-defunct Board of Scientific Advisors.

September 19, 2025

Vol.51 No.34

By Sara Willa Ernst

AACR Cancer Progress Report makes the case for federal investment in cancer research

As NCI and NIH funding is being deliberated in Congress, this year’s 2025 AACR Cancer Progress Report had an unequivocal message: With 20 new anticancer therapeutics, new uses for eight previously approved anticancer therapeutics, two new early detection tools, and several AI-powered diagnostics approved over the span of just one year, cancer research funding yields a good return on investment.

Urgently needed: A funding mechanism to insulate cancer research from political whims

Jonathan Mahler’s article in the Sept. 14 issue of The New York Times Magazine provided an excellent overview of the Trump administration’s assault on cancer research.

How today’s uncertainty can motivate young investigators to double down on their passion
Lessons from my Studs Terkel boxed set

The Cancer Letter has published a number of excellent pieces lately on the importance of supporting and encouraging trainees and junior investigators during these uncertain times.

Ousted CDC director testifies before Senate HELP Committee

Ousted from her position as director of the Centers for Disease Control and Prevention less than a month after her confirmation, Susan Monarez has now had the chance to tell her side of the story before Congress.

September 19, 2025

Vol.51 No.34

By Claire Marie Porter

Boehringer Ingelheim and CureVac announce collaboration.

YOU MAY BE INTERESTED IN

NCI is “really, really sturdy” and won’t break, former directors Ned Sharpless and Kim Rathmell say at UNC Lineberger symposium

NCI releases names of members of ad hoc working group—filling the void left by BSA

AACR Cancer Progress Report makes the case for federal investment in cancer research

Urgently needed: A funding mechanism to insulate cancer research from political whims

How today’s uncertainty can motivate young investigators to double down on their passion
Lessons from my Studs Terkel boxed set

Ousted CDC director testifies before Senate HELP Committee

Renew today!

Subscriber content

Never miss an issue!

Login

Boehringer Ingelheim and CureVac announce collaboration.

YOU MAY BE INTERESTED IN

NCI is “really, really sturdy” and won’t break, former directors Ned Sharpless and Kim Rathmell say at UNC Lineberger symposium

NCI releases names of members of ad hoc working group—filling the void left by BSA

AACR Cancer Progress Report makes the case for federal investment in cancer research

Urgently needed: A funding mechanism to insulate cancer research from political whims

How today’s uncertainty can motivate young investigators to double down on their passionLessons from my Studs Terkel boxed set

Ousted CDC director testifies before Senate HELP Committee

Never miss an issue!

Login

How today’s uncertainty can motivate young investigators to double down on their passion
Lessons from my Studs Terkel boxed set